Patient P-02297

Synthetic patientMETA-24 · Day 178 · 35–44 · F · baseline S02Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Unstable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

69%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S02
Day 47 NP-02 recommended — Dietary Support Protocol NP-02
Day 48 Patient accepted — Started NP-02 in the companion
Day 58 GI symptom burden −21% vs expected — Dietary Support Protocol NP-02
Day 64 Tolerance state changed — Unstable → Improving
Day 80 GI-04 recommended — GI Support Protocol GI-04
Day 81 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 81 Patient accepted — Started GI-04 in the companion
Day 89 No meaningful change — GI Support Protocol GI-04
Day 90 ME-01 recommended — Monitoring Escalation ME-01
Day 91 Patient accepted — Started ME-01 in the companion
Day 94 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 81.

Primary contributors, last 14 days

Toxicity+16
Nutritional resilience-7
GI instability-6

What helped?

Dietary Support Protocol NP-02Day 47
Result: symptom burden −21%
GI Support Protocol GI-04Day 80
Result: no meaningful change
Monitoring Escalation ME-01Day 90
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Supportive Compound SC-12

56%

probability of meaningful tolerance improvement

284 similar trajectories
69% showed improvement
median effect visible after 6 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

24 min

stable · +0.6 vs previous 14 d

Sleep duration

Wearable

5.2 h

stable · -0.1 vs previous 14 d

Energy level

Daily log

1.6/10

improving · +0.1 vs previous 14 d

Steps

Wearable

2,494

stable · -38 vs previous 14 d

GI burden

Companion

66/100

stable · +1.2 vs previous 14 d

Adherence

Companion

46.6 %

worsening · -4.0 vs previous 14 d

Sleep quality

Wearable

11.2/100

worsening · -1.8 vs previous 14 d

Glucose, CGM daily mean

CGM

162 mg/dL

stable · +2.6 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 25 from the failing basin, 70 from restoration.

Would help

SC-12 Supportive Compound
69% improved among 26 similar · onset 6 d · confidence 64%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 64%
More protein
GI -6.7 next day on high-intake days · n 21

Would not help

GI-04 GI Support Protocol
already tried, no meaningful change
Keep caffeine low
GI +6.4 next day on high-intake days · n 23
Keep ultra-processed low
GI +6.3 next day on high-intake days · n 19
Keep fat low
GI +6.1 next day on high-intake days · n 24

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Protein
-6.7supporter · 95%
Caffeine
+6.4detractor · 95%
Ultra-processed food
+6.3detractor · 95%
Dietary fat load
+6.1detractor · 95%
Insoluble fibre
+3.8detractor · 89%
Alcohol
+3.8detractor · 82%
Simple carbohydrates
+3no signal · 54%
Histamine load
-0.7no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 64
- WearableHRV 16 ms, trending down
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 32/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 66 and rising
- WearableSleep 5.2 h, below personal baseline
Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 58
Autonomic recovery ↓40
- Wearable2,494 steps/day
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Poor metabolizer
Higher exposure at standard dose
GLP1R rs6923761 A
Altered receptor sensitivity

Microbiome

Shannon diversity 2.3 · butyrate capacity 32/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 27 ms
Sleep: 5.3 h
Steps: 3,714
Resting HR: 69 bpm

Daily log: GI score 66, nutritional resilience 31, adherence 47.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02552	18%	S07	AD-05	no change	29
P-02483	19%	S06	BR-03	no change	64
P-02564	18%	S15	BR-03	improved	32
P-02151	35%	S04	CR-01	improved	49
P-02025	33%	S15	CR-01	improved	61
P-02054	30%	S01	CR-01	improved	57
P-02009	28%	S08	CR-01	improved	64
P-02154	27%	S16	CR-01	improved	57
P-02233	25%	S16	CR-01	improved	66
P-02395	19%	S12	DT-01	improved	57
P-02491	19%	S09	DT-01	no change	65
P-02274	18%	S15	DT-01	improved	50